Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
Merck(MRK) ZACKS·2024-07-01 10:30
Merck (MRK) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has given a positive opinion recommending the approval of its pulmonary arterial hypertension (PAH) drug Winrevair (sotatercept) in Europe. The CHMP recommended Winrevair in combination with other PAH therapies for treating adult patients with PAH (WHO Functional Class II to III) to improve exercise capacity.The decision of the European Commission is expected in the third quarter of 2024. If ...